ABSI
Absci Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 36.37K | $325,139 | n/a | n/a |
| Q2 2026 | 82 | +7 | 112.04M | $1.30B | +11 | −4 |
| Q1 2026 | 77 | +13 | 90.86M | $272.61M | +16 | −3 |
| Q4 2025 | 64 | 0 | 89.20M | $311.30M | n/a | n/a |
| Q3 2025 | 15 | -1 | 60.11M | $182.75M | +1 | −2 |
| Q2 2025 | 13 | 0 | 50.18M | $128.95M | +2 | −2 |
| Q1 2025 | 10 | 0 | 17.56M | $44.09M | +1 | −1 |
| Q4 2024 | 10 | 0 | 15.09M | $39.55M | +1 | −1 |
| Q3 2024 | 9 | 0 | 11.86M | $45.29M | +1 | −1 |
| Q2 2024 | 9 | n/a | 12.14M | $37.33M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 36.37K | +5.9% | $325,139 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 159 holders, 118.34M shares, $354.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.